ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: We found that treatment of CML cells with 2‐DG, which blocks glycolysis and thereby lactate production, or monocarboxylate transporter (MCT) inhibitors, which reduce lactate excretion, enhanced BCR/Ablprotein expression and promoted maintenance of a BCR/Abl‐dependent/TKI‐sensitive stem cell phenotype.